Skip to main content
Premium Trial:

Request an Annual Quote

Europroteome, Abbott Collaborate on Breast Cancer Diagnostics Development

NEW YORK, March 1 (GenomeWeb News) - Abbott Laboratories has entered a research collaboration with Europroteome to discover and develop in vitro diagnostic tests for the early detection of breast cancer, the companies said today.

 

Under the deal, Europroteome will use its proteomics and bioinformatics technologies to analyze serum samples from women with breast cancer. The resultant data will be aligned with a panel of cancer markers from Abbott. Combinations of markers will be selected for further development and integration into Abbott's instrument platforms, the companies said.

 

Abbott will pay Europroteome an upfront fee, as well as milestone payments. Abbott will also have an option for a royalty-bearing license to the results from the research collaboration, and well be responsible for commercial assay development and marketing.

 

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.